Dr. Wanmei Wang Appointed as Chief Medical Officer and SVP at Trinomab; Company Submits IPO Prospectus
Trinomab
Developer of Natural Fully Human Monoclonal Antibody New Drugs
Trinomab, a company dedicated to the development and industrialization of natural fully human monoclonal antibody therapeutics, recently announced the formal appointment of Dr. Wanmei Wang as its Chief Medical Officer (CMO) and Senior Vice President (SVP). Dr. Wang brings over 20 years of operational and management experience in new drug development, clinical research, and medical affairs within the biopharmaceutical industry. In her new role at Trinomab, she will be primarily responsible for overseeing clinical development, regulatory strategy, and clinical operations for the company’s product pipeline in China, the United States, and globally.
Ms. Wanmei Wang graduated from Southern Medical University and earned her Ph.D. at the Rigshospitalet, Copenhagen University Hospital, in Denmark. She has nearly 20 years of experience in clinical practice and medical research.
Prior to joining Trinomab, Dr. Wang served as Chief Medical Officer (CMO) at a startup focused on anti-infective therapies, where he efficiently advanced several anti-infective projects from the preclinical stage to clinical development. Previously, he was the General Manager of China R&D at Ferring Pharmaceuticals, a multinational corporation. In this role, he established, operated, and managed an international pharmaceutical research center in Beijing, China, while building a robust clinical development pipeline in China that drove eight clinical development projects from Phase I through the completion of Phase III studies. He also served as Vice President of Clinical Development at CStone Pharmaceuticals, where he was responsible for project management, formulation of clinical development strategies, pharmacovigilance, and analysis of medical trends and clinical research dynamics.
Wang Guanmei possesses extensive experience in clinical protocol design for new drugs, development of IND-to-Phase III clinical trials, and communication and negotiation with regulatory authorities for NDA submissions and global approvals. Her development projects span therapeutic areas including antivirals, oncology, and autoimmune diseases, with a geographic scope covering China, Europe, the United States, Australia, India, and other countries.
“I am deeply honored to join Trinomab, an international, dynamic, and promising company dedicated to the research, development, and industrialization of novel antibody-based therapeutics. I look forward to working with the Trinomab team to further refine our processes for clinical trial applications and management, strengthen our clinical development team, and enable Trinomab to conduct high-quality clinical studies of its product candidates,” said Dr. Wang Guanmei.
“We warmly welcome Dr. Wang Guanmei to our team,” said Dr. Liao Huaxin, Chairman and Chief Technology Officer of the Company. “Dr. Wang brings extensive experience in clinical drug development and team management. Her addition will undoubtedly provide stronger clinical development strategies for Trinomab’s pipeline products, accelerating their path to market and ultimately benefiting patients worldwide.”
“Ms. Wang Guanmei brings over 20 years of global pharmaceutical business experience and possesses keen insights into the global clinical research and regulatory landscape. Her joining plays a pivotal role in mitigating clinical development risks for Trinomab’s pipeline products and advancing their global strategic layout,” stated Mr. Zheng Weihong, Co-founder, CEO, and President of Trinomab.
About Trinomab
Zhuhai Trinomab Biotechnology Co., Ltd. (hereinafter referred to as “Trinomab”) is a global, clinical-stage innovative biopharmaceutical company primarily engaged in the research and development of original, natural fully human monoclonal antibody therapeutics. Trinomab’s core technology is the “HitmAb® Platform for Integrated Development of Natural Fully Human Monoclonal Antibodies,” which is dedicated to developing highly differentiated, efficacious natural fully human monoclonal antibody drugs with independent intellectual property rights, so as to enhance and improve the prevention and treatment outcomes for infectious diseases, autoimmune diseases, malignant tumors, and other conditions.
Currently, the company has multiple new products undergoing rapid industrialization, with some having entered clinical trial stages. In addition to the recombinant anti-tetanus toxin natural fully human monoclonal antibody TNM002, which has successively received Investigational New Drug (IND) approvals in both China and the United States, the clinical trial application for the “Recombinant Anti-Respiratory Syncytial Virus Natural Fully Human Monoclonal Antibody Drug TNM001 Injection” was accepted by the National Medical Products Administration (NMPA) on May 24.
Trinomab has completed multiple rounds of financing, with investors including Hillhouse Capital, CMS Pharmaceutical Group, WuXi Biologics Industrial Fund, and Wuxi State-owned Union Group. Trinomab’s ultimate goal is to establish itself as an international biopharmaceutical company dedicated to the research, development, and production of natural fully human monoclonal antibody therapeutics. You are welcome to follow our official WeChat account: purplebull
Zhuhai Trinomab Biotechnology Co., Ltd.
Zhuhai R&D Center: 2nd Floor, No. 6C, Zhizao Avenue, Hongqi Town, Jinwan District, Zhuhai City
Zhuhai Production Base: Building 9, International Health Port, Sanzao Town, Jinwan District, Zhuhai City
Beijing Clinical Center: Room W2-911, Oriental Plaza, Dongcheng District, Beijing
US Office: 4307 Forest Edge Trail, Durham, NC 27705, USA
Australian Office: 17 Bungowen Ave, Thornleigh, NSW Australia 2120
Tel: 0756-7263999
Email: trinomab@trinomab.com
Related Reports:
2. Trinomab: Focused on the Development of Natural Fully Human Antibody Therapeutics
3. Trinomab’s Digital Antibody Production Base Officially Completed and Commences Operations!
4. Mr. Li Bin Officially Joins Trinomab as Vice President of Clinical Development
5. Trinomab Announces Completion of RMB 450 Million Series A Financing
6. Congratulations to Trinomab on the NMPA Approval of IND for TNM002 Monoclonal Antibody